Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal
Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
